Intra-Cellular on track for another Caplyta label expansion after positive Ph3 depression data

In­tra-Cel­lu­lar Ther­a­pies’ Caply­ta sig­nif­i­cant­ly im­proved symp­toms in a late-stage ma­jor de­pres­sive dis­or­der tri­al, mark­ing a step in the drug’s jour­ney to be­com­ing a pipeline-in-a-pill.

Atyp­i­cal an­tipsy­chot­ic Caply­ta is al­ready ap­proved for schiz­o­phre­nia and bipo­lar de­pres­sion. Ac­cord­ing to Jef­feries an­a­lysts, the drug is “be­com­ing a pipeline-in-a-pill” and could reach $2 bil­lion in peak sales in these two in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.